Literature DB >> 7791229

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

F X Bosch1, M M Manos, N Muñoz, M Sherman, A M Jansen, J Peto, M H Schiffman, V Moreno, R Kurman, K V Shah.   

Abstract

BACKGROUND: Epidemiologic studies have shown that the association of genital human papillomavirus (HPV) with cervical cancer is strong, independent of other risk factors, and consistent in several countries. There are more than 20 different cancer-associated HPV types, but little is known about their geographic variation.
PURPOSE: Our aim was to determine whether the association between HPV infection and cervical cancer is consistent worldwide and to investigate geographic variation in the distribution of HPV types.
METHODS: More than 1000 specimens from sequential patients with invasive cervical cancer were collected and stored frozen at 32 hospitals in 22 countries. Slides from all patients were submitted for central histologic review to confirm the diagnosis and to assess histologic characteristics. We used polymerase chain reaction-based assays capable of detecting more than 25 different HPV types. A generalized linear Poisson model was fitted to the data on viral type and geographic region to assess geographic heterogeneity.
RESULTS: HPV DNA was detected in 93% of the tumors, with no significant variation in HPV positivity among countries. HPV 16 was present in 50% of the specimens, HPV 18 in 14%, HPV 45 in 8%, and HPV 31 in 5%. HPV 16 was the predominant type in all countries except Indonesia, where HPV 18 was more common. There was significant geographic variation in the prevalence of some less common virus types. A clustering of HPV 45 was apparent in western Africa, while HPV 39 and HPV 59 were almost entirely confined to Central and South America. In squamous cell tumors, HPV 16 predominated (51% of such specimens), but HPV 18 predominated in adenocarcinomas (56% of such tumors) and adenosquamous tumors (39% of such tumors).
CONCLUSIONS: Our results confirm the role of genital HPVs, which are transmitted sexually, as the central etiologic factor in cervical cancer worldwide. They also suggest that most genital HPVs are associated with cancer, at least occasionally. IMPLICATION: The demonstration that more than 20 different genital HPV types are associated with cervical cancer has important implications for cervical cancer-prevention strategies that include the development of vaccines targeted to genital HPVs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791229     DOI: 10.1093/jnci/87.11.796

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  661 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Immunohistochemical analysis, human papillomavirus DNA detection, hormonal manipulation, and exogenous gene expression of normal and dysplastic human cervical epithelium in severe combined immunodeficiency mice.

Authors:  J A Taylor; K Tewari; S Y Liao; C C Hughes; L P Villarreal
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins.

Authors:  B A Glaunsinger; S S Lee; M Thomas; L Banks; R Javier
Journal:  Oncogene       Date:  2000-11-02       Impact factor: 9.867

4.  Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible.

Authors:  Philip E Castle; Attila T Lorincz; Iwona Mielzynska-Lohnas; David R Scott; Andrew G Glass; Mark E Sherman; John E Schussler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

5.  A novel strategy for human papillomavirus detection and genotyping with SybrGreen and molecular beacon polymerase chain reaction.

Authors:  K Szuhai; E Sandhaus; S M Kolkman-Uljee; M Lemaître; J C Truffert; R W Dirks; H J Tanke; G J Fleuren; E Schuuring; A K Raap
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  Screening for cervical cancer: should we test for infection with high-risk HPV?

Authors:  C J Meijer; P J Snijders; A J van den Brule
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

7.  Distribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay.

Authors:  I Nindl; B Lotz; R Kühne-Heid; U Endisch; A Schneider
Journal:  J Clin Pathol       Date:  1999-01       Impact factor: 3.411

8.  RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells.

Authors:  Allison H S Hall; Kenneth A Alexander
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

9.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

10.  Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens.

Authors:  J U Cope; A Hildesheim; M H Schiffman; M M Manos; A T Lörincz; R D Burk; A G Glass; C Greer; J Buckland; K Helgesen; D R Scott; M E Sherman; R J Kurman; K L Liaw
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.